Brain tumour patients at an NHS hospital in England were left on chemotherapy for years longer than they should have been, with some suffering severe harm, a damning independent review has found.
The Royal College of Physicians (RCP) examined care at University Hospitals Coventry and Warwickshire NHS Trust (UHCW) and concluded that patients were given repeated courses of the chemotherapy drug temozolomide — known as TMZ — long after the treatment should have stopped. Some were misdiagnosed, while others were told they would die if they stopped taking the drug, even though that was not true.
The review, published on Wednesday, looked at 20 cases of patients treated under a now-retired consultant clinical oncologist. Of those, 15 were judged to have received care that was unsatisfactory overall, and the other five were found to require improvement. Not a single case was rated as good practice.
Working to strict definitions of harm, the review team concluded that six patients had suffered severe harm, five had suffered moderate harm and eight had suffered low levels of harm. In the final case, reviewers could not reach a judgement on whether the harm was moderate or severe.
TMZ is a powerful chemotherapy drug used for certain brain tumours, including glioblastoma, the most aggressive form. It is normally given for six cycles over around six months after radiotherapy. But at the Coventry trust, some patients received it for more than a decade.
In the worst example uncovered by the review, a patient was given more than 100 cycles of chemotherapy over 13 years before doctors realised the original diagnosis had been wrong. The patient later developed acute myeloid leukaemia, a fast-growing blood cancer, as a side-effect of the excessive treatment. Developing a second cancer is a known risk of prolonged exposure to drugs such as TMZ.
Another patient, Becky Jones, was 21 when she was told she had a grade 4 glioblastoma and only six to 12 months to live. She went on to receive more than 100 cycles of temozolomide over more than a decade. Independent experts later concluded that she had never had a brain tumour at all, and that her scans were consistent with tumefactive demyelination, a far less serious condition. One woman told the BBC she received more than 150 rounds of the drug over at least 12 years, leaving her housebound and with her quality of life badly affected.
David Bown, who was diagnosed with a brain tumour in 2016, suffered permanent neurological damage following complications after surgery and was then treated with TMZ for more than eight years. His condition has since deteriorated further, and he has now lost the ability to speak.
The review found that extended treatment was repeatedly continued despite clear evidence of toxicity or deterioration in the patient’s condition, with little or no evidence of benefit. It also identified serious concerns about incorrect or insufficiently supported diagnoses, inadequate documentation of informed consent, and a lack of effective challenge from other members of the clinical team. Grade 3 tumours were treated in the same way as grade 4 glioblastomas, the report said, with no individualised approach to each patient’s care.
The trust commissioned the review after the retirement of the doctor at the centre of the findings. He is referred to as Dr Y in the report, but the trust has named him as Professor Ian Brown, a clinical oncologist employed there from 1996 to 2024. Concerns about his practice were raised by colleagues when his patients were handed over to them after he retired in December 2023. Professor Brown did not take part in the review and declined to comment when approached by the BBC at his home.
The RCP warned that the number of patients affected is likely to be far higher than the 20 cases it examined. It found that 83 patients received extended TMZ treatment between 2017 and 2023 alone, and it has recommended that every living patient who received more than 12 cycles of the drug should have their case independently reviewed.
More than 40 patients have now come forward, represented by the law firm Brabners, and are calling for an independent public inquiry. Cases have been referred to the police, although no action has been taken as yet.
The trust has apologised. Its chief executive, Professor Andy Hardy, and chairwoman Sue Noyes said in a statement that they offered their sincere apologies to the patients and families affected. The trust spent more than £3.6 million on temozolomide between 2007 and 2023 — over ten times the amount spent by comparable NHS hospitals.
For the patients and families involved, the findings confirm years of suffering that could have been avoided. For the NHS, they raise searching questions about how one doctor’s practice could go unchallenged for so long, and how many more patients may still be waiting to learn whether their own treatment was necessary.
Source: BBC News — https://www.bbc.co.uk/news (reporting on the Royal College of Physicians review into University Hospitals Coventry and Warwickshire NHS Trust, published 18 November 2026)